Cargando…

Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial

INTRODUCTION: This study was performed to evaluate the degree of 3-day chemotherapy-induced nausea and vomiting (CINV) in children with cancer who received highly emetogenic chemotherapy (HEC) to ascertain the efficacy of aprepitant single-dose on dayL 1 plus granisetron and dexamethasone (DEX). MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eghbali, Aziz, Kohpar, Fatemeh Khazaei, Ghaffari, Kazem, Afzal, Roghayeh Rahimi, Eghbali, Aygin, Ghasemi, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499563/ https://www.ncbi.nlm.nih.gov/pubmed/35428609 http://dx.doi.org/10.1016/j.htct.2022.02.004

Ejemplares similares

The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
por: Eghbali, Aziz, et al.
Publicado: (2023)

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
por: Kang, Jin Hyoung, et al.
Publicado: (2020)

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
por: Miya, Toshimichi, et al.
Publicado: (2016)

Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer
por: Fujiwara, Satoe, et al.
Publicado: (2015)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
por: Cheng, Yi, et al.
Publicado: (2022)

Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
por: Hingmire, Sachin, et al.
Publicado: (2015)

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2021)

Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial
por: Sun, Der Sheng, et al.
Publicado: (2023)

Magnesium Supplementation May Not Be Protective against Carboplatin-Induced Nephrotoxicity But May Be Beneficial for Children Suffering Malignancies: A Randomized Clinical Trial
por: Alizadeh Hadadhania, Marzie, et al.
Publicado: (2023)

Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy
por: Toda, Haruka, et al.
Publicado: (2017)

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens
por: Yoshida, Naohisa, et al.
Publicado: (2019)

Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study
por: Wakasugi, Yoshinori, et al.
Publicado: (2019)

Comparison of granisetron plus dexamethasone versus an antiemetic cocktail containing midazolam and diphenhydramine for chemotherapy induced nausea and vomiting in children
por: Emir, Suna, et al.
Publicado: (2013)

5HT(3)RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy‐induced nausea and vomiting in colorectal cancer
por: Hayashi, Toshinobu, et al.
Publicado: (2020)

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
por: Chrisp, Paul
Publicado: (2007)

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
por: Escobar, Yolanda, et al.
Publicado: (2015)

Granisetron Versus Dexamethasone in Prophylaxis of Nausea and Vomiting After Laparoscopic Cholecystectomy
por: Hessami, Mohammad Ali, et al.
Publicado: (2012)

The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron.
por: Aapro, M. S., et al.
Publicado: (1994)

Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
por: Escobar, Yolanda, et al.
Publicado: (2015)

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study
por: Boccia, Ralph V., et al.
Publicado: (2010)

Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)
por: Shimizu, Hisanori, et al.
Publicado: (2018)

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010)

Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting
por: Nijstad, A. Laura, et al.
Publicado: (2022)

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review
por: Tuca, Albert
Publicado: (2009)

Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy‐Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial
por: van der Vorst, Maurice J.D.L., et al.
Publicado: (2020)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study
por: Yokokawa, Takashi, et al.
Publicado: (2023)

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis
por: Botteman, Marc, et al.
Publicado: (2019)

Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial
por: Wang, De-Shen, et al.
Publicado: (2021)

Postoperative nausea and vomiting prophylaxis: A comparative study of ondansetron, granisetron and granisetron and dexamethasone combination after modified radical mastectomy
por: Gupta, Pushplata, et al.
Publicado: (2014)

Granisetron versus Granisetron-Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Pediatric Strabismus Surgery: A Randomized Double-Blind Trial
por: Sinha, Renu, et al.
Publicado: (2016)

Granisetron plus dexamethasone for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic surgery: A meta-analysis
por: Zhu, Min, et al.
Publicado: (2017)

Cost‐effectiveness of aprepitant in Japanese patients treated with cisplatin‐containing highly emetogenic chemotherapy
por: Tsukiyama, Ikuto, et al.
Publicado: (2018)

Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy
por: Boccia, Ralph V, et al.
Publicado: (2012)

A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients
por: Jang, Geundoo, et al.
Publicado: (2013)

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy
por: Sigsgaard, T, et al.
Publicado: (1999)

Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK
por: Humphreys, Samantha, et al.
Publicado: (2013)

Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis
por: Qiu, Tingting, et al.
Publicado: (2020)

Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
por: Qiu, Tingting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vfe5a1qq55n6ecs3rlpohsno4s